?Product Name?: Ethyl 7-Chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (Ozenoxacin Intermediate A)
?CAS No.?: 103877-51-6
?Molecular Formula?: C??H??ClNO?
?Molecular Weight?: 292.74

?? ?Product Overview?

?Brief Introduction?: A critical intermediate in the synthesis of ?Ozenoxacin?, a non-fluorinated quinolone antibacterial agent used to treat superficial skin infections like impetigo. This high-purity compound ensures efficient production of the final API (Active Pharmaceutical Ingredient).
?Primary Function?: Key building block for ?Ozenoxacin? synthesis, enabling precise structural modification in pharmaceutical manufacturing.
?Applicable Fields?: Antibacterial drug development, API production, and fine chemical research.

? ?Key Advantages?

?? ?≥99% Purity?: Verified by HPLC and NMR, ensuring compliance with pharmaceutical-grade standards.
?? ?Bulk Availability?: Offered in flexible quantities (1g to 25kg) with rapid delivery options.
?? ?Stability?: Long-term storage stability under controlled conditions (room temperature, dry environment).

?? ?Application Scenarios?

• ?Ozenoxacin Synthesis?: Essential for manufacturing the non-fluorinated quinolone antibacterial agent.

• ?API Development?: Used in preclinical and commercial stages for antibacterial drug formulations.

• ?Research Use?: Supports studies on quinolone derivatives and antimicrobial resistance mechanisms.

?? ?Quality Certifications?

• ?Testing Standards?: Complies with USP/EP guidelines; validated by HPLC (>99%), NMR, and mass spectrometry.

• ?Documentation?: COA, HPLC, and NMR reports provided for regulatory compliance.

?? ?Market Trends?

Demand for this intermediate is rising due to the expanding use of ?Ozenoxacin? in treating antibiotic-resistant skin infections, particularly in pediatric populations. The Asia-Pacific region dominates production, driven by pharmaceutical companies scaling API manufacturing post-patent expiration.